Arrivent Biopharma, Inc. (NASDAQ: AVBP) has recently appointed Merdad Parsey, M.D., Ph.D. to its board of directors. Dr. Parsey has extensive executive experience in the biopharmaceutical industry, having most recently served as the Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc.
Arrivent's chairman and CEO, Bing Yao, expressed excitement at Dr. Parsey's appointment, highlighting his track record of driving therapeutic innovation and strategic growth in the pharmaceutical and biotech sectors. Dr. Parsey's appointment comes at a crucial time for Arrivent as they continue to progress Firmonertinib towards registration and advance their pipeline of antibody drug conjugate (ADC) programs.
Prior to joining Gilead, Dr. Parsey held key positions at Genentech, Inc., a member of the Roche Group, where he oversaw clinical development, quality, compliance, informatics, and clinical operations functions. He also has experience as the President and CEO of 3-V Biosciences, Inc., now Sagimet Biosciences, Inc., and has served on the board of directors since 2010. Dr. Parsey's earlier career included roles at Sepracor, Inc., Regeneron Pharmaceuticals, Inc., Merck, Inc., and a tenure as an assistant professor of medicine and director of critical care medicine at New York University School of Medicine.
Dr. Parsey's educational background includes an M.D. and Ph.D. in immunology from the University of Maryland, Baltimore, a residency in internal medicine at Stanford University, and a fellowship in pulmonary and critical care medicine at the University of Colorado.
Arrivent is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines to address the unmet medical needs of cancer patients. The company aims to leverage its team's deep drug development experience to maximize the potential of its lead development candidate, Firmonertinib, and advance a pipeline of novel therapeutics, including next-generation antibody drug conjugates, through approval and commercialization.
The addition of Dr. Parsey to Arrivent's board of directors brings a wealth of experience and expertise to the company as it continues its mission to bring innovative biopharmaceutical therapeutics to the global market. Today the company's shares have moved -0.7% to a price of $20.68. For the full picture, make sure to review ArriVent BioPharma's 8-K report.
